Concentric Analgesics highlights data on vocacapsaicin for pain relief
Vocacapsaicin has demonstrated significant pain relief and early opioid cessation post-surgery in Phase II clinical trials.
mental health conditions
Study finds semaglutide decreases tobacco-related healthcare
FDA approves Luye Pharma’s ERZOFRI for schizophrenia
Johnson & Johnson submits sNDA for SPRAVATO to treat depression
Enveric Biosciences to out-license psilocin prodrug to MindBio
Clearmind licenses psychedelic compounds for mental disorders
Enveric’s EB-003 selected as lead candidate for mental health disorders
Waning focus on abuse potential may negatively affect pipeline non-stimulants for ADHD
